Abstract:Background: Diabetic retinopathy (DR) stands as a prominent complication of diabetes. Berberine (BBR) has reported to be effective to ameliorate the retinal damage of DR. Studying the potential immunological mechanisms of BBR on the streptozotocin (STZ) induced DR mouse model will explain the therapeutic mechanisms of BBR and provide theoretical basis for the clinical application of this drug. Methods: C57BL/6 J mice were induced into a diabetic state using a 50 mg/(kg & sdot;d) dose of STZ over a 5 -day period. Subsequently, they were subjected to a high -fat diet (HFD) for one month. Following a 5 -week treatment with 100 mg/(kg & sdot;d) BBR, the concentrations of inflammatory factors in the mice 's peripheral blood were determined using an enzyme -linked immunosorbent assay (ELISA). Hematoxylin-eosin staining was employed to scrutinize pathological changes in the mice 's retinas, while flow cytometry assessed the proportions of Tlymphocyte subsets and the activation status of dendritic cells (DCs) in the spleen and lymph nodes. CD4 + T cells and DC2.4 cell lines were utilized to investigate the direct and indirect effects of BBR on T cells under high glucose conditions in vitro. Results: Following 5 weeks of BBR treatment in the streptozotocin (STZ) mouse model of DR, we observed alleviation of retinal lesions and a down -regulation in the secretion of inflammatory cytokines, namely TNF- alpha, IL1 beta, and IL -6, in the serum of these mice. And in the spleen and lymph nodes of these mice, BBR inhibited the proportion of Th17 cells and promoted the proportion of Treg cells, thereby down -regulating the Th17/Treg ratio. Additionally, in vitro experiments, BBR directly inhibited the expression of the transcription factor ROR gamma t and promoted the expression of the transcription factor Foxp3 in T cells, resulting in a down -regulation of the Th17/Treg ratio. Furthermore, BBR indirectly modulated the Th17/Treg ratio by suppressing the secretion of TNF- alpha, IL-1 beta, and IL -6 by DCs and enhancing the secretion of indoleamine 2,3-dioxygenase (IDO) and transforming growth factor -beta (TGF- beta) by DCs. This dual action inhibited Th17 cell differentiation while promoting Treg cells. Conclusion: Our findings indicate that BBR regulate T cell subpopulation differentiation, reducing the Th17/Treg ratio by directly or indirectly pathway. This represents a potential therapeutic avenue of BBR for improving diabetic retinopathy.

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress

Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‐18a‐3p/Gsdmd pathway

Berberine Pretreatment Confers Cardioprotection Against Ischemia–Reperfusion Injury in a Rat Model of Type 2 Diabetes

Berberine Treatment Prevents Cardiac Dysfunction and Remodeling Through Activation of 5′-Adenosine Monophosphate-Activated Protein Kinase in Type 2 Diabetic Rats and in Palmitate-Induced Hypertrophic H9c2 Cells

Berberine Improves Kidney Function in Diabetic Mice via AMPK Activation

Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/mtROS axis to alleviate diabetic cardiomyopathy

Myricitrin Alleviates Oxidative Stress-induced Inflammation and Apoptosis and Protects Mice against Diabetic Cardiomyopathy

Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy

Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation

Protective Effects of Berberine on Nonalcoholic Fatty Liver Disease in db/db Mice via AMPK/SIRT1 Pathway Activation

Berberine Improves Insulin Resistance in Cardiomyocytes Via Activation of 5′-Adenosine Monophosphate-Activated Protein Kinase

Berberine plays a cardioprotective role by inhibiting macrophage Wnt5a/β‐catenin pathway in the myocardium of mice after myocardial infarction

Berberine improves cognitive impairment by alleviating brain atrophy and promoting white matter reorganization in diabetic db/db mice: a magnetic resonance imaging-based study

Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats.

Berberine Alleviates Diabetic Retinopathy by Regulating the Th17/Treg Ratio.

Berberine Alleviates the Damage, Oxidative Stress and Mitochondrial Dysfunction of PC12 Cells Induced by High Glucose by Activating the KEAP1/Nrf2/ARE Pathway

Bakuchiol Alleviates Hyperglycemia-Induced Diabetic Cardiomyopathy by Reducing Myocardial Oxidative Stress Via Activating the SIRT1/Nrf2 Signaling Pathway.

Berberine protects human and rat cardiomyocytes from hypoxia/reoxygenation-triggered apoptosis.

Berberine Protects Against Diabetic Retinopathy by Inhibiting Cell Apoptosis Via Deactivation of the NF‑κB Signaling Pathway.

Berberine inhibits excessive autophagy and protects myocardium against ischemia/reperfusion injury via the RhoE/AMPK pathway

Berberine ameliorates chronic intermittent hypoxia‐induced cardiac remodelling by preserving mitochondrial function, role of SIRT6 signalling